BR0011152A - Péptidos inibidores da exocitosis neurónica, composições cosméticas e farmacêuticas que os contêm - Google Patents

Péptidos inibidores da exocitosis neurónica, composições cosméticas e farmacêuticas que os contêm

Info

Publication number
BR0011152A
BR0011152A BR0011152-0A BR0011152A BR0011152A BR 0011152 A BR0011152 A BR 0011152A BR 0011152 A BR0011152 A BR 0011152A BR 0011152 A BR0011152 A BR 0011152A
Authority
BR
Brazil
Prior art keywords
neuronic
cosmetic
pharmaceutical compositions
compositions containing
exocytosis
Prior art date
Application number
BR0011152-0A
Other languages
English (en)
Inventor
Gregorio Fernandez Ballester
Mercedes Llobregat Hernandez
Clara Blanes Mira
Rosa Planells Cases
Antonio Ferrer Montiel
Salvador Viniegra Bover
Anabel Gil Tebar
Luis Miguel Gutierrez Perez
Teresa Carbonell Castello
Enrique Perez Paya
Original Assignee
Lipotec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8308129&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0011152(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lipotec Sa filed Critical Lipotec Sa
Publication of BR0011152A publication Critical patent/BR0011152A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PéPTIDOS INIBIDORES DA EXOCITOSIS NEURóNICA, COMPOSIçõES COSMéTICAS E FARMACêUTICAS QUE OS CONTêM". O péptido tem uma sequência de 3 a 30 amino-ácidos contíguos procedentes do extremo amino da proteína SNAP-25 e é útil como inibidor da exocitosis neurónica. As composições cosméticas e farmacêuticas compreendem o mencionado péptido, opcionalmente junto com um ou mais péptidos procedentes do extremo carboxilo da SNAP-25. As composições são adequadas para o tratamento das rugas faciais, da assimetria facial e de transtornos e alterações patológicas mediadas por uma exócitosis neurónica patológica.
BR0011152-0A 1999-04-23 2000-02-18 Péptidos inibidores da exocitosis neurónica, composições cosméticas e farmacêuticas que os contêm BR0011152A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009900844A ES2160485B1 (es) 1999-04-23 1999-04-23 Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
PCT/ES2000/000058 WO2000064932A1 (es) 1999-04-23 2000-02-18 Peptitos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen

Publications (1)

Publication Number Publication Date
BR0011152A true BR0011152A (pt) 2002-02-19

Family

ID=8308129

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0011152A BRPI0011152B8 (pt) 1999-04-23 2000-02-18 peptídeos inibidores da exocitose neuronal, mistura de peptídeos, composições cosméticas e farmacêuticas, utilização de um peptídeo, e, método para o tratamento cosmético em um ser humano das rugas faciais e/ou da assimetria facial
BR0011152-0A BR0011152A (pt) 1999-04-23 2000-02-18 Péptidos inibidores da exocitosis neurónica, composições cosméticas e farmacêuticas que os contêm

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0011152A BRPI0011152B8 (pt) 1999-04-23 2000-02-18 peptídeos inibidores da exocitose neuronal, mistura de peptídeos, composições cosméticas e farmacêuticas, utilização de um peptídeo, e, método para o tratamento cosmético em um ser humano das rugas faciais e/ou da assimetria facial

Country Status (12)

Country Link
US (2) US7015192B1 (pt)
EP (1) EP1180524B2 (pt)
JP (2) JP4363556B2 (pt)
AT (1) ATE338062T1 (pt)
AU (1) AU2672900A (pt)
BR (2) BRPI0011152B8 (pt)
CA (1) CA2370289C (pt)
DE (1) DE60030429T3 (pt)
DK (1) DK1180524T4 (pt)
ES (1) ES2160485B1 (pt)
PT (1) PT1180524E (pt)
WO (1) WO2000064932A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2160485B1 (es) * 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
EP1301213B1 (en) 2000-07-21 2017-01-18 ReVance Therapeutics, Inc. Multi-component biological transport systems
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
FR2846885B1 (fr) * 2002-11-13 2004-12-24 Oreal Utilisation d'une association de composants a effet synergique inhibiteur de canaux calciques pour prevenir ou traiter les ridules
US7071167B2 (en) 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
JP2004323400A (ja) * 2003-04-23 2004-11-18 Mikimoto Pharmaceut Co Ltd 皮膚外用剤
CA2558676C (en) 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CN1946431B (zh) 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
US20060073208A1 (en) 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
CA2584643C (en) * 2004-11-02 2013-01-29 Pentapharm Ag New, topically applicable actives against mimic and age-related wrinkles
SG160357A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
CN101160318A (zh) 2005-03-03 2008-04-09 雷文斯治疗公司 用于局部施用和经皮肤递送寡肽的组合物和方法
ES2259928B1 (es) * 2005-04-08 2007-11-01 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica que comprende peptidos derivados de encefalinas para reducir y/o eliminar arrugas faciales.
NZ568216A (en) 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
WO2007071448A2 (en) * 2005-12-23 2007-06-28 Partnership & Corp. Technology Transfer Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
ES2322882B1 (es) * 2006-10-25 2010-04-22 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal.
EP1992332A1 (en) * 2007-05-08 2008-11-19 Tupperware Products S.A. Cosmetic anti ageing skin care compositions
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
JP5782439B2 (ja) * 2009-07-24 2015-09-24 リポテック, エセ.ア.Lipotec, S.A. 筋肉収縮を抑制する化合物
US20130078295A1 (en) * 2010-06-09 2013-03-28 Lipotec S.A. Skin antiaging treatment
US20110305735A1 (en) * 2010-06-09 2011-12-15 Lipotec, S.A. Skin antiaging treatment
ES2385683B1 (es) * 2010-10-18 2013-10-07 Bcn Peptides, S.A. Composiciones para el tratamiento del dolor y/o la inflamación.
WO2013070808A1 (en) * 2011-11-07 2013-05-16 Feng Tian Peptide-based compounds as inhibitors of neurotransmitter secretion
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
US10149812B2 (en) 2012-04-13 2018-12-11 Activen Cosmetic composition comprising a muconopeptide
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
WO2013153236A2 (en) 2012-04-13 2013-10-17 Activen Cosmetic composition comprising a muconopeptide
EP2836193B1 (en) 2012-04-13 2018-01-31 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (ii)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
WO2015063613A2 (en) 2013-11-01 2015-05-07 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
MX394677B (es) 2014-10-31 2025-03-24 Lubrizol Advanced Mat Inc Pelicula de poliuretano termoplastico para la liberacion de agentes activos a superficies de piel.
CN104478991B (zh) * 2014-12-10 2018-06-19 深圳市维琪医药研发有限公司 一种新型多肽化合物及其制备方法和其医药应用
CN104829691B (zh) * 2015-05-19 2018-11-02 山西锦波生物医药股份有限公司 除皱短肽及其制备方法
US20180311358A1 (en) 2015-11-05 2018-11-01 Lubrizol Advanced Materials, Inc. Thermoformable dual network hydrogel compositions
ES2937382T3 (es) 2018-02-27 2023-03-28 Lipotrue S L Péptidos y composiciones para uso en cosmética y medicina
WO2019238683A1 (en) 2018-06-13 2019-12-19 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. Peptides having inhibitory activity on neuronal exocytosis
EP3833674A1 (en) 2018-08-10 2021-06-16 Lubrizol Advanced Materials, Inc. Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes
JP2022514114A (ja) 2018-10-16 2022-02-09 ジーエルオー ファーマ，インク． ニコチン性アセチルコリン受容体ペプチドアンタゴニストであるコノトキシン組成物、およびこれに関連する方法
MX2020014330A (es) * 2018-12-26 2021-03-09 Caregen Co Ltd Composicion para relajacion muscular.
EP4144337B1 (en) 2021-09-02 2024-08-07 Guangzhou Jiyan Cosmetics Technology Co. Ltd. Vitis vinifera cosmetic composition
CN113826764B (zh) * 2021-09-24 2024-07-12 江苏三仪生物工程有限公司 一种大豆小肽螯合铁的制备方法
EP4230638A1 (en) 2022-02-16 2023-08-23 Lipotrue, S.L. Peptides and compositions for use in cosmetics
US20250161409A1 (en) 2022-02-23 2025-05-22 Prospera Biotech, S.L. Compositions for treating hyperhidrosis
CN117203217B (zh) 2022-03-28 2024-11-29 深圳市维琪科技股份有限公司 一种多肽及其组合物和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169074B1 (en) * 1996-03-18 2001-01-02 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
ES2160485B1 (es) * 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.

Also Published As

Publication number Publication date
CA2370289C (en) 2011-04-19
DE60030429D1 (de) 2006-10-12
EP1180524A1 (en) 2002-02-20
BRPI0011152B8 (pt) 2022-05-10
ES2160485B1 (es) 2002-05-16
EP1180524B1 (en) 2006-08-30
DE60030429T3 (de) 2012-01-12
WO2000064932A1 (es) 2000-11-02
BRPI0011152B1 (pt) 2018-03-13
DK1180524T3 (da) 2006-12-11
JP2002542777A (ja) 2002-12-17
EP1180524B2 (en) 2010-07-07
JP4363556B2 (ja) 2009-11-11
US20060276392A1 (en) 2006-12-07
US7473679B2 (en) 2009-01-06
JP4892037B2 (ja) 2012-03-07
DK1180524T4 (da) 2010-10-25
JP2009221223A (ja) 2009-10-01
ATE338062T1 (de) 2006-09-15
CA2370289A1 (en) 2000-11-02
US7015192B1 (en) 2006-03-21
DE60030429T2 (de) 2007-10-31
AU2672900A (en) 2000-11-10
ES2160485A1 (es) 2001-11-01
PT1180524E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
BR0011152A (pt) Péptidos inibidores da exocitosis neurónica, composições cosméticas e farmacêuticas que os contêm
PT1200105E (pt) Factor viii modificado
AR053063A2 (es) Proteina sustancialmente purificada y composicion farmaceutica que la comprende
ATE254448T1 (de) Kosmetische oder dermatologische zusammensetzung, enthaltend zumindest ein natürliches oder rekombinantes seidenprotein von arachniden oder ein analoges protein
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
TW200833365A (en) Neuronal exocytosis inhibiting peptides
DE60012137D1 (de) Acetylenische alpha-amino-säuren auf basis von sulfonamid-hydroxamsäuren als tace-inhibitoren
ATE365749T1 (de) Humane peptide/proteine, die das töten von zellen,einschliesslich lymphoide tumorzellen, herbeiführen oder bewirken
JP2018505890A5 (pt)
ATE6251T1 (de) Acylpeptide und pharmazeutische praeparate davon, sowie deren herstellung und verwendung.
SE0002202D0 (sv) New peptides
Tsuzaki et al. Tendon collagens: extracellular matrix composition in shear stress and tensile components of flexor tendons
BR0308860A (pt) Fator viii modificado
ES2052583T3 (es) Derivados de peptidos relacionados con el gel calcitonina.
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
BR9809103A (pt) Forma farmacêutica estável de administração para peptìdeos, proteìnas e ácidos nucléicos
Gildberg et al. Angiotensin I-converting enzyme inhibitory activity in a hydrolysate of proteins from Northern shrimp (Pandalus borealis) and identification of two novel inhibitory tri-peptides
BRPI0606445A2 (pt) inibidores de hipersecreÇço de mucina e mÉtodos de uso
FI964186A0 (fi) Ei-liittävät gp350/220-variantit
BR9712128A (pt) Métodos e composições para lipidização de moléculas hidrofìlicas
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
KR940007059A (ko) 변형된 혈소판 인자-4
BR0014803A (pt) Peptìdeo, composição farmacêutica, uso de um ou mais dos peptìdeos, e, composição de diagnóstico
AR019851A1 (es) Proteina sustancialmente pura con actividad similar a scarface 3 in vivo o in vitro; analogos de proteina scarface 3; aislados de compuestos de acidosnucleicos que codifican dichas proteinas; vectores que incluyen dichos compuestos de acidos nucleicos; celulas huespedes que poseen dichos vectores yf

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: LIPOTEC, S.A. (ES)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/02/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 18/02/2020

B22E Other requirements [chapter 22.5 patent gazette]

Free format text: FORMULADA EXIGENCIA PARA ADEQUACAO OU CUMPRIMENTO DE DISPOSICOES LEGAIS NO PRAZO DE 60 (SESSENTA) DIAS DESTA DATA.

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA.

B21I Extinguishment of a patent or of a certificate of addition of invention: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 21.1 NA RPI NO 2630 DE 01/06/2021 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2462, DE 13/03/2018. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 13/03/2018, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.